This new research category award recognises Cell Signaling Technology as the company doing best in the global cancer biology market.

From the data generated through CiteAb we are able to gain a really clear picture of the way antibodies are used around the world. We can tell which countries are investing most in research using antibodies, which companies are seeing growth or decline, which antibodies are most successful and which areas of research are seeing growth.

Dr Andrew Chalmers, Founder of CiteAb, said: “The winner for this award was established based on CiteAb data for the most citations achieved in the cancer biology market between January 2017 and December 2017. Cell Signaling Technology should be proud to be supporting more cancer researchers than any other supplier.”